Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.

Processes of making [1.1.1]propellane utilize reaction conditions that include reacting 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane with an effective amount of solid magnesium.

Processes for making bicyclic compounds and precursors thereof, and particularly for making [1.1.1]propellane and bicyclo[1.1.1]pentane and derivatives thereof, utilize continuous flow reaction methods and conditions. A continuous process for making [1.1.1]propellane can be conducted under reaction conditions that advantageously minimize clogging of a continuous flow reactor. A continuous flow process can be used to make precursors of [1.1.1]propellane.

Processes of making [1.1.1]propellane utilize reaction conditions that include reacting 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane with an effective amount of solid magnesium.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. ##STR00001##

A resist composition comprising a quencher containing a sulfonium salt having the formula (A). ##STR00001##

Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.

##STR00001##

A resist composition comprising a quencher containing a sulfonium salt having the formula (A).

##STR00001##

Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.

The invention is directed to methods of producing alkoxylated or hydroxylated terpenes comprising the steps of continuously passing a solution comprising an alcohol in combination with a terpene over an acidic resin catalyst in a packed bed reactor in order to yield a product, as well as compounds that are the products of the methods described herein.